ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028

Lifesciences | Pharmaceuticals

ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028

Market By Device Type, Route Of Administration, End-user, And Country | Forecast 2019-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The Asia-Pacific injectable drug delivery market is expected to make progress at a CAGR of 9.66% in terms of revenue throughout the estimated period 2019-2028.



Report scope can be customized per your requirements. Request For Customization

The countries studied in this market include:

           India

           Japan

           China

           Australia & New Zealand

           ASEAN countries

           South Korea

           Rest of APAC countries

The Chinese drug delivery market is primarily being driven by the growing prevalence of cancer, an increase in the number of hospitals, the need to deliver better-quality healthcare services, and the increasing focus to boost the biologics sector. Cancer nanoparticle-based drug delivery systems show immense potential as a mode of cancer treatment. The rising number of cancer cases is, therefore, raising the demand for these systems. This increased demand, in turn, is fuelling China’s injectable drug delivery market growth over the forecast period.

Also, the data from 2016 WHO studies suggest that the percentage of R&D investments in top Chinese firms reached 5% of the total revenues. And the highest percentage of this expenditure was contributed to by the biologics sector. For instance, Suzhou’s Innovent Biologics, based in China, collaborated with Eli Lily and Company, raising approx. $450 million for commercializing three new cancer treatments. The increasing expenditure on biologics is aiding the companies’ R&D teams to develop novel drug delivery technologies. These factors are enhancing the adoption of injectable drug delivery technologies in China, which is expected to favor its market growth.

In Australia, the number of cancer patients is expected to rise by a staggering 17,000 people, in the three year period from 2017-2020. Nanoparticles, which are a crucial element of nanomedicines, have garnered special interest, as they are being looked upon as promising drug delivery systems for cancer treatment. Therefore, the growing number of cancer patients in the country is helping the growth of the studied market in Australia over the forecasting period.

Established in 1921, Terumo Corporation is a company that is engaged in the design, manufacture, and commercialization of medical products and equipment. PLAJEX, one of the products offered by the company, consists of prefillable syringes with staked needles. Terumo is headquartered in Tokyo, Japan. The company invests heavily in R&D as it believes in continuous innovation to maintain its leading position in the industry.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCES MODEL

2.2.1.   THREAT OF NEW ENTRANT

2.2.2.   THREAT OF SUBSTITUTE

2.2.3.   BARGAINING POWER OF BUYERS

2.2.4.   BARGAINING POWER OF SUPPLIERS

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. KEY INSIGHT

2.4. KEY BUYING CRITERIA

2.5. MARKET ATTRACTIVENESS INDEX

2.6. MARKET DRIVERS

2.6.1.   INCREASING GERIATRIC POPULATION

2.6.2.   TECHNOLOGICAL ADVANCEMENT

2.6.3.   GROWING OCCURRENCE OF AUTOIMMUNE DISEASES

2.7. MARKET RESTRAINTS

2.7.1.   HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS

2.8. MARKET OPPORTUNITIES

2.8.1.   DEVELOPMENT OF BETTER INJECTABLE SYSTEMS

2.8.2.   INCREASE IN HEALTHCARE EXPENDITURE

2.9. MARKET CHALLENGES

2.9.1.   DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS

2.9.2.   STRINGENT REGULATIONS

3.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE

3.1. PEN INJECTOR

3.2. AUTO-INJECTOR

3.3. NEEDLE-FREE INJECTOR

3.4. PREFILLED SYRINGE

4.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION

4.1. SUBCUTANEOUS

4.2. INTRAMUSCULAR

4.3. INTRAVENOUS (IV)

4.4. OTHER ROUTE OF ADMINISTRATION

5.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER

5.1. CLINICS/ PHYSICIAN OFFICES

5.2. AMBULATORY CARE

5.3. HOSPITAL

5.4. HOME-BASED

5.5. OTHER END-USERS

6.    INJECTABLE DRUG DELIVERY MARKET – ASIA-PACIFIC

6.1. COUNTRY ANALYSIS

6.1.1.   JAPAN

6.1.2.   CHINA

6.1.3.   AUSTRALIA & NEW ZEALAND

6.1.4.   INDIA

6.1.5.   SOUTH KOREA

6.1.6.   ASEAN COUNTRIES

6.1.7.   REST OF ASIA-PACIFIC

7.    COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC

7.2. BECTON DICKINSON AND COMPANY (BD)

7.3. ELCAM MEDICAL

7.4. ELI LILLY AND COMPANY

7.5. GERRESHEIMER

7.6. INJEX

7.7. NOVARTIS AG

7.8. NOVO NORDISK A/S

7.9. PFIZER INC

7.10.  SANOFI SA

7.11.   SCHOTT AG

7.12.  TERUMO CORPORATION

7.13.  TEVA PHARMACEUTICALS

7.14.  WEST PHARMACEUTICALS

7.15.  YPSOMED HOLDING AG

8.    RESEARCH METHODOLOGY & SCOPE

8.1. RESEARCH SCOPE & DELIVERABLES

8.1.1.   OBJECTIVES OF STUDY

8.1.2.   SCOPE OF STUDY

8.2. SOURCES OF DATA

8.2.1.   PRIMARY DATA SOURCES

8.2.2.   SECONDARY DATA SOURCES

8.3. RESEARCH METHODOLOGY

8.3.1.   EVALUATION OF PROPOSED MARKET

8.3.2.   IDENTIFICATION OF DATA SOURCES

8.3.3.   ASSESSMENT OF MARKET DETERMINANTS

8.3.4.   DATA COLLECTION

8.3.5.   DATA VALIDATION & ANALYSIS

List of table

TABLE  1       ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)

TABLE  2       ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)

TABLE  3       DIFFERENT TYPES OF INSULIN PEN INJECTORS

TABLE  4       MARKETED NEEDLE-FREE INJECTORS PRODUCTS

TABLE  5       LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE

TABLE  6       ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)

TABLE  7       ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)

TABLE  8       ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)   

List of Figures

FIGURE  1     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  2     KEY BUYING IMPACT ANALYSIS

FIGURE  3     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)

FIGURE  4     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)

FIGURE  5     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)

FIGURE  6     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)

FIGURE  7     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)

FIGURE  8     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR, 2019-2028 ($ MILLION)

FIGURE  9     ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS, 2019-2028 ($ MILLION)

FIGURE  10  ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)

FIGURE  11  ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/ PHYSICIAN OFFICES, 2019-2028 ($ MILLION)

FIGURE  12  ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)

FIGURE  13  ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)

FIGURE  14  ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)

FIGURE  15  ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)

FIGURE  16  JAPAN INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  17  CHINA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  18  AUSTRALIA & NEW ZEALAND INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  19  INDIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  20  SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  21  ASEAN COUNTRIES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  22  REST OF ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;